Core Viewpoint - Far East China (02789) has seen a significant stock price increase of nearly 25%, currently trading at 0.191 HKD, with a transaction volume of 10.4792 million HKD, ahead of its mid-year earnings announcement scheduled for August 29 [1] Financial Performance - The company anticipates a net profit of approximately 150 million to 210 million CNY for the first half of the year, compared to 6 million CNY in the same period last year [1] - The growth in net profit is attributed to the successful implementation of the internationalization strategy, which has led to substantial contributions from overseas market orders and an increase in foreign exchange gains compared to the same period in 2024 [1] Business Overview - Shenyang Far East (Far East China) is an independent listed company primarily engaged in curtain wall construction, recognized as one of the first approved companies for Grade A design and Grade 1 construction in China [1] - The company provides comprehensive curtain wall solutions and has a global business presence [1] Revenue Breakdown - In 2024, the company's revenue from China is projected to be 1.02 billion CNY, accounting for 46% of total revenue, making it the largest revenue region [1] - The United States and the United Kingdom are the second-largest markets, each contributing approximately 240 million CNY, representing about 11% of total revenue [1] - Revenue from Qatar is expected to be 200 million CNY, accounting for 9% of total revenue [1]

Market Overview - The Hong Kong stock market continued its downward trend, with all three major indices in the red but maintaining above the 25,000 mark. The Hang Seng Index closed down 0.98% at 25,270.07 points, with a total turnover of HKD 31.27 billion [1] - Short-term market focus is on mid-year performance and cost-effectiveness, with potential volatility from US-China trade negotiations and fluctuations in US stocks [1] Blue-Chip Stocks Performance - JD Health (06618) led blue-chip stocks, rising 11.67% to HKD 61.25, contributing 11.31 points to the Hang Seng Index. The company's H1 2025 performance exceeded market expectations due to strong growth in the pharmaceutical category [2][4] - Other notable blue-chip movements included Xinyi Solar (00968) up 5.96%, Alibaba Health (00241) up 4.92%, while New World Development (00016) and Henderson Land (00012) saw declines of 5.35% and 4.63% respectively [2] Sector Highlights - Internet healthcare stocks showed strong performance, with Dingdang Health (09886) up 36.07% and JD Health (06618) up 11.67% following strong mid-year results [3][4] - The brokerage sector saw significant gains, with CITIC Securities (06066) up 10.98% and Zhongtai Securities (01375) up 9.03%, reflecting a structural shift in fund flows towards financial markets [5][6] - The photovoltaic sector also experienced gains, driven by a shortage and price increases in solar components, with Xinyi Solar (00968) rising 8.15% [6][7] Regulatory Developments - The Hong Kong Monetary Authority and the Securities and Futures Commission issued a joint statement regarding recent market fluctuations related to stablecoins, emphasizing a cautious approach to licensing [8] Notable Stock Movements - Silver诺医药-B (02591) surged 206.48% on its debut, reflecting strong market interest in GLP-1 drug treatments [9] - Liken Technology (00558) rose 46.02% following a strategic partnership for magnesium alloy humanoid robot development [10] - Far East China (02789) saw an 84.34% increase after announcing a profit forecast for H1 2025, driven by international market orders [11][12] - Jin Hai Medical Technology (02225) fell 50.56% after announcing a share subscription at a discount to market price [13]

董事會會議通知 Yuanda China Holdings Limited 2789 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部分內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 遠大中國控股有限公司（「本公司」）董事會（「董事會」）謹此通知，董事會會議將於2025年8 月29日（星期五）舉行，以考慮及酌情通過（其中包括）本公司及其附屬公司截至2025年6月 30日止六個月之未經審核合併中期業績及其刊發及處理任何其他事項（如有）。 承董事會命 遠大中國控股有限公司 於本公告日期，本公司執行董事為康寶華先生、趙忠秋先生、王昊先生及張雷先生；及 本公司獨立非執行董事為王宇航先生、楊倩雯女士及哈剛先生。 主席 康寶華 中國，2025年8月15日 ...

8月14日，远大中国发布公告，该集团预期于2025年上半年取得净利润约1.5亿至2.1亿元，2024年同期净 利润为600万元。公告称，净利增长的主要原因是该期间内集团国际化战略取得良好进展，海外市场订 单贡献突出，使得集团该期间的收入规模较2024同期取得增长，及该期间集团汇兑收益较2024年同期取 得增长。 来源：新浪港股 远大中国（02789）盈喜后飙升逾60%，截至发稿，股价上涨56.63%，现报0.130港元，成交额527.041万 港元。 ...

智通财经获悉，远大中国(02789)盈喜后飙升逾60%，截至发稿，涨60.24%，报0.133港元，成交额 317.44万港元。 消息面上，8月14日，远大中国发布公告，该集团预期于2025年上半年取得净利润约1.5亿-2.1亿元， 2024年同期净利润为600万元。公告称，净利增长的主要原因是该期间内集团国际化战略取得良好进 展，海外市场订单贡献突出，使得集团该期间的收入规模较2024同期取得增长，及该期间集团汇兑收益 较2024年同期取得增长。 本文源自：智通财经网 ...

Core Viewpoint - Far East Global (02789) experienced a surge of over 60% in stock price following a profit warning, with shares trading at HKD 0.133 and a transaction volume of HKD 3.1744 million [1] Group 1: Financial Performance - The company anticipates a net profit of approximately HKD 150 million to HKD 210 million for the first half of 2025, compared to a net profit of HKD 6 million in the same period of 2024 [1] - The significant increase in net profit is attributed to the successful implementation of the company's internationalization strategy, which has led to substantial contributions from overseas market orders [1] Group 2: Revenue Growth - The company expects revenue growth for the period compared to the same period in 2024, driven by increased orders from international markets [1] - Additionally, the company reported an increase in foreign exchange gains compared to the same period in 2024, further contributing to the anticipated profit growth [1]

Core Viewpoint - Far East China Holdings Limited (远大中国) experienced a significant stock price increase of 49.4% on August 15, reaching HKD 0.124 per share, with a trading volume of HKD 2.7212 million [1] Company Overview - Far East China is a leading global enterprise in the construction curtain wall industry, providing high-quality curtain wall products and services [1] - The company has completed over 3,100 engineering projects and has installed more than 65 million square meters of curtain walls [1] - It operates 1,150 sets of advanced automated processing equipment, capable of meeting an annual demand of 13 million square meters [1] - The company has established R&D institutions in 12 regions worldwide, employing over 1,500 technical personnel [1] - R&D expenditure accounts for 2.3% to 3.6% of revenue, resulting in the continuous development of new products and the acquisition of 831 patents [1] Financial Performance - As of the 2024 annual report, the company reported total revenue of RMB 2.212 billion and a net loss of RMB 354 million [1] - On August 14, the company projected a significant increase in mid-2025 interim performance, with estimated profits ranging from RMB 150 million to RMB 210 million, representing a year-on-year growth of 2,400% to 3,400% [1]

Group 1: Core Insights - Rongchang Biologics (09995.HK) announced that its innovative drug Taitasip (brand name: Tai Ai®) for treating primary Sjögren's syndrome has met the primary endpoint in a Phase III clinical trial in China [1] - Taitasip is the first BLyS/APRIL dual-target fusion protein drug to complete Phase III research in the field of Sjögren's syndrome globally [1] - The clinical trial was a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Taitasip, with the primary endpoint being the change in ESSDAI score at week 24 compared to baseline [1] Group 2: Disease Background and Drug Mechanism - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and damage to exocrine glands, leading to persistent dry mouth and dry eyes, and can affect multiple organ systems [2] - The prevalence of Sjögren's syndrome in China is estimated to be between 0.3% and 0.7%, with an increasing trend indicating a significant unmet clinical need [2] - Taitasip is a novel dual-target fusion protein developed by the company that simultaneously inhibits the overexpression of BLyS and APRIL, effectively preventing abnormal differentiation and maturation of B cells [2] Group 3: Regulatory and Clinical Recognition - Taitasip has received multiple authoritative guideline recommendations in China, including the "Clinical Practice Guidelines for Sjögren's Syndrome" and the "Expert Consensus on B-cell Targeted Therapy for Rheumatic and Immune Diseases" [2] - Internationally, Taitasip has been granted Fast Track designation by the U.S. FDA for its indication in Sjögren's syndrome and has been approved to conduct global multi-center Phase III clinical trials [2]

Group 1 - The company, Far East Horizon (02789), expects to achieve a net profit of approximately 150 million to 210 million yuan in the first half of 2025, compared to a net profit of 6 million yuan in the same period of 2024 [1] - The primary reason for the profit growth is the successful progress of the company's internationalization strategy, which has led to significant contributions from overseas market orders [1] - The company also reported an increase in exchange gains during the period compared to the same period in 2024, contributing to the overall revenue growth [1]

董事会认为，该期间的业绩取得增长的主要原因是(i)该期间内集团国际化战略取得良好进展，海外市场 订单贡献突出，使得集团该期间的收入规模较2024同期取得增长，及(ii)该期间集团汇兑收益较2024年 同期取得增长。 格隆汇8月14日丨远大中国(02789.HK)发布公告，集团预计截至2025年6月30日止六个月录得净利润介于 约人民币150百万元至人民币210百万元，较2024年同期录得的净利润人民币约6.0百万元有显著改善。 ...